Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Dynavax, GlaxoSmithKline Battling In Same Industry: Who Will Win?


Slingshot Insights recently conducted an interview with Dr. Ashwin Balagopal, assistant professor of medicine at the Johns Hopkins University School of Medicine about the impact that Dynavax Technologies Corporation (NASDAQ: DVAX)’s HBV-23 will have on the HBV vaccine market, particularly when it comes to GlaxoSmithKline plc (ADR) (NYSE: GSK)’s Engerix-B.

When asked about the Phase III Dynavax data that was released in January, Dr. Balagopal said that it looks very promising.

“What I’ve seen of the data that were released is that the Dynavax vaccine appears to be as effective if not more effective, at least in the generation of protective antibody fighters for hepatitis B prevention, after only 2 doses,” Dr. Balagopal explained. “Having it be two doses rather than three doses is certainly preferable because you’re going to miss a lot of people for whom you’re insisting on three doses.”

Related Link: Valeant Had A 58% Chance Of Bankruptcy Last Year

When asked about the potential market share that a Dynavax vaccine could achieve, Dr. Balagopal said that the size of the market likely wouldn’t change much, but Dynavax could potentially take over the vast majority of the current market.

“The market would be the same, it would just be better and having a better vaccine means that you can give fewer doses. That might certainly mean that the Dynavax vaccine is going to be widespread because of it, but it would be equally widespread.”

Disclosure: the author holds no position in the stocks mentioned.

Posted-In: Dr. Ashwin Balagopal Slingshot InsightsAnalyst Color Biotech Interview General


Related Articles (DVAX + GSK)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Target Gets the Opportunity to Stand Out Among Big Box Retailers

Crocs' Cornerstone Patent Rejected By U.S. Patent Office